Tirzepatide represents a genuine pharmacological breakthrough. As the first approved dual agonist targeting both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor, it achieves glycemic control and weight loss outcomes that exceed those of selective GLP-1 receptor agonists alone. Marketed by Eli Lilly as Mounjaro (type 2 diabetes), Zepbound (obesity and, since December 2024, moderate-to-severe obstructive sleep apnea), tirzepatide is one of the most commercially significant drugs in the world.
That commercial significance — combined with a period of supply shortage from 2022 through 2024 — created an unprecedented compounding market, widespread independent quality testing of compounded products, and a growing regulatory and quality data record that now makes tirzepatide one of the most analytically documented therapeutic peptides. This guide covers the complete testing landscape for tirzepatide: the drug’s structural properties and their implications for analytical chemistry, the full suite of laboratory tests applied from drug substance manufacturing through clinical use, the compounding quality issues revealed by independent testing, and the dramatically changed regulatory environment as of April 2026.
For pharmaceutical developers, CROs, compounding pharmacies, and quality assurance teams seeking accredited pharmaceutical testing laboratories for tirzepatide analysis, ContractLaboratory.com connects you with qualified labs experienced in therapeutic peptide testing. Submit a testing request to get started.
Tirzepatide: Structural Properties and Analytical Implications
Understanding tirzepatide’s unique chemistry is essential for selecting appropriate analytical methods — its structural complexity creates challenges that differ significantly from simpler peptides and from semaglutide.
Tirzepatide is a 39-amino acid synthetic acylated peptide with a molecular weight of approximately 4,813.45 Da. Its sequence incorporates several non-natural amino acids, including Aib (alpha-aminoisobutyric acid) substitutions that confer protease resistance and extend half-life. The defining structural feature is a C20 fatty diacid moiety attached to the epsilon-amino group of Lys26 via a gamma-glutamic acid-mini-PEG linker. This lipidation enables albumin binding, which extends the plasma half-life to approximately 5 days in humans, supporting once-weekly subcutaneous dosing.
The analytical consequences of this structure include:
- Chromatographic behavior: The C20 fatty acyl chain significantly increases hydrophobicity and alters retention on standard peptide columns. Reversed-phase HPLC analysis requires wider-pore stationary phases — 300 angstrom C18 or C4 columns — and shallower acetonitrile gradients compared to unmodified peptides. Standard 100-130 angstrom columns used for small peptides produce poor peak shape and resolution for tirzepatide.
- Mass spectrometry: Positive electrospray ionization produces multiple charge states. The dominant signal in LC-MS/MS bioanalysis is the [M+5H]5+ ion at m/z 1204.4, with the [M+4H]4+ at m/z 1204.6 and [M+3H]3+ also observed. Oxidized degradation products (e.g., mono-oxidized tirzepatide from tryptophan oxidation) appear at m/z 1208.1 (5+) — a shift of +16 Da corresponding to oxygen incorporation.
- Solution behavior: Tirzepatide exists as a trimer in solution (MW ~13,000 Da for the trimer). This oligomeric state affects SEC analysis, where the protein runs at a higher apparent molecular weight than the monomer mass suggests, and must be taken into account when interpreting aggregation data.
- Manufacturing complexity: Tirzepatide is produced via a hybrid solid-phase/liquid-phase peptide synthesis (SPPS/LPPS) strategy using four shorter peptide fragment intermediates (each 10-14 amino acids), which are purified individually before liquid-phase coupling to form the full-length drug substance. Each fragment requires validated impurity characterization methods by UHPLC-UV and UHPLC-MS.
Critical Regulatory Update: Tirzepatide Compounding Status (2025-2026)
The regulatory timeline for tirzepatide compounding through April 2026:
- December 2022 – October 2024: Tirzepatide on FDA Drug Shortage List. 503A compounding pharmacies and 503B outsourcing facilities permitted to compound tirzepatide as an essentially a copy exception under the drug shortage exemption.
- October 2, 2024: FDA determined the tirzepatide shortage was resolved — Eli Lilly’s supply could meet national demand. Initial removal from the shortage list.
- October 7, 2024: Outsourcing Facilities Association filed suit in the US District Court (N.D. Texas) challenging the FDA’s determination. The court remanded the case to the FDA for reevaluation.
- December 19, 2024: The FDA issued a declaratory order reaffirming that the shortage was resolved. Established enforcement discretion periods: 503A pharmacies until February 18, 2025; 503B outsourcing facilities until March 19, 2025.
- February 18, 2025, and March 19, 2025: Enforcement discretion periods ended. Routine compounding of products essentially copying Mounjaro or Zepbound became a violation of the FD&C Act.
- May 2025: US District Court for the Northern District of Texas upheld the FDA’s decision to remove tirzepatide from the shortage list. Legal challenges continued through appeals.
- As of April 2026: Routine compounding of tirzepatide is not legally permitted. Limited compounding may still occur under Section 503A for individual patients where a prescriber documents a specific clinical need that cannot be met by commercially available Mounjaro or Zepbound, but a mass-compounded product is not permitted. Litigation regarding the shortage determination continues at the appellate level.
This regulatory reversal has transformed the tirzepatide testing market. During the shortage period, the primary demand for third-party testing came from compounding pharmacies verifying product quality and from patients/researchers seeking to confirm the purity and potency of compounded products. In the post-shortage environment, the testing audience has shifted toward: pharmaceutical manufacturing quality control by Eli Lilly and contract manufacturers; CROs supporting clinical trials; and regulatory submission support for biosimilar and generic tirzepatide development as the market evolves.
Compounding Quality Issues: What Independent Testing Revealed
The period of legal tirzepatide compounding (2022–2025) generated a substantial body of independent quality testing data that illuminates both why rigorous pharmaceutical testing matters and what can go wrong without robust quality controls.
Potency and purity discrepancies
Independent testing data for GLP-1 receptor agonists during the compounding period showed alarming rates of discrepancy between supplier-claimed purity and independently verified purity. GLP-1 peptides — including tirzepatide — demonstrated the highest purity discrepancy rate of any peptide category, with published testing data showing that a substantial majority of supplier Certificates of Analysis (COAs) did not match independent HPLC and LC-MS/MS results. Many samples tested below label-claimed purity, and fill weight discrepancies in lyophilized vials were also documented, with some vials containing significantly more or less tirzepatide than labeled.
FDA received more than 320 reports of adverse events associated with compounded tirzepatide as of early 2025, reflecting both the scale of compounding and the quality issues that arose in less rigorously controlled production environments.
The tirzepatide-B12 adduct impurity
A significant quality issue emerged in 2025-2026 research: a novel impurity formed in mass-compounded combination products containing tirzepatide combined with hydroxocobalamin or methylcobalamin (vitamin B12 analogues). Research characterized this as a tirzepatide-B12 adduct — a covalent or strong non-covalent interaction product between tirzepatide and B12, detected by MS and confirmed by 1D and 2D NMR. This adduct was present at substantial levels in compounded combination products but is absent from Eli Lilly’s approved formulations.
The functional impact of this adduct — including potential effects on binding to GIP and GLP-1 receptors, altered pharmacokinetics (ADME), and long-term safety — is unknown, underscoring why rigorous identity and impurity characterization by LC-MS/MS and NMR is essential for any tirzepatide product.
Tirzepatide Analytical Testing Methods: Quick Reference
| Method | What it detects | ICH/USP guideline | Key specification | Application stage |
| RP-HPLC / UHPLC-UV | Purity, related substance impurities, degradation products; quantification of individual and total impurities | ICH Q2(R1) method validation; ICH Q3 impurities; ICH Q6B | Drug substance: >/=98% purity (pharma grade); individual impurities typically <0.1-0.2% w/w | DS/DP release; incoming material QC; stability indicating |
| UHPLC-MS (ESI-MS) | Identity confirmation by accurate mass; impurity identification; fragment characterization; adduct detection | ICH Q6B; USP <1030> Biological Assays | Molecular weight: 4813.45 Da monomer; [M+5H]5+ at m/z 1204.4 confirmed | DS identity; impurity characterization; adduct/modification detection |
| LC-MS/MS (bioanalysis) | Tirzepatide plasma/urine concentration in PK/PD studies; metabolite identification; bioavailability | FDA/EMA bioanalytical method validation (2018 guidance); ICH M10 | LLOQ typically 1 ng/mL; dynamic range 1-1000 ng/mL; accuracy within +/-15%; precision CV <15% | PK studies; clinical trials; bioavailability; drug-drug interactions |
| SEC (Size Exclusion Chromatography) | Aggregates, oligomers, high-molecular-weight species; tirzepatide trimer (~13,000 Da) and dimer characterization | ICH Q6B; USP <1127> | Monomer purity specified; HMWS (high molecular weight species) typically <2% for release | DS/DP characterization; aggregation during stability; formulation development |
| Capillary electrophoresis (CE) | Per product specification, the charge variant profile established as a reference for batch comparison | ICH Q6B; USP <1053> | Endotoxin contamination from gram-negative bacteria — a critical safety test for all injectables | DS/DP characterization; stability monitoring; process consistency |
| Peptide mapping (LC-MS/MS) | Sequence confirmation at individual AA level; post-synthetic modifications; disulfide bonds; acylation site (Lys26) verification | ICH Q6B; USP <1054> | Full sequence coverage; correct acylation at Lys26 confirmed | DS structural characterization; comparability studies; biosimilar development |
| Bacterial Endotoxins (BET/LAL) | Absence of viable microorganisms in the injectable product | USP <85> Bacterial Endotoxins Test; Ph. Eur. 2.6.14 | <1.0 EU/mL for parenteral products (per 21 CFR 610.13 and ICH Q6B) | DP release; compounding QC — mandatory for all injectable formulations |
| Sterility testing | Biological activity at GIP and GLP-1 receptors confirms functional integrity beyond structural identity | USP <71> Sterility Tests; Ph. Eur. 2.6.1 | No growth in 14-day incubation in SCDM (20-25 °C) and FTM (30-35 °C) | DP final release; compounding final product verification |
| Potency / identity assay | Per product specification, receptor binding assay or cell-based cAMP assay | ICH Q6B; USP <1033> | Per product specification; receptor binding assay or cell-based cAMP assay | DS/DP release; stability (demonstrating potency retention) |
| Stability testing (ICH) | Degradation under thermal, photolytic, oxidative, and hydrolytic stress; shelf-life determination | ICH Q1A(R2); ICH Q5C for biologics | Potency/identity assay | DS/DP development; shelf-life determination; compounding dating |
Key Test Categories in Detail
Drug Substance Purity and Impurity Testing (RP-HPLC/UHPLC)
Reversed-phase HPLC with UV detection at 210-215 nm (peptide bond absorbance) is the workhorse method for tirzepatide purity assessment. Because of the C20 fatty acyl chain, standard 100-130 angstrom pore C18 columns provide inadequate resolution. Wide-pore columns (300 angstrom pore C18 or C4, 2.1 or 4.6 mm ID) with peptide-optimized mobile phases (aqueous TFA or formic acid/acetonitrile gradients) are required.
For pharmaceutical-grade drug substance (as in Mounjaro/Zepbound), the specification is typically >/=98% purity with each specified related substance below 0.1-0.2% w/w and total impurities below 2%. For the SPPS/LPPS manufacturing process used for tirzepatide, UHPLC-MS methods were developed specifically for quantitation of peptide fragment-related impurities that co-elute with the main peak in UV chromatograms — validated per ICH Q2(R1) across the range of 0.1% to 1.0% w/w per the USP Workshop on Therapeutic Peptides (2022).
Bioanalytical Testing: LC-MS/MS for Pharmacokinetics
Quantitative measurement of tirzepatide concentrations in biological matrices (plasma, serum, urine) uses LC-MS/MS with electrospray ionization in positive mode. Published validated methods achieve a lower limit of quantitation (LLOQ) of 1 ng/mL in plasma, with linear dynamic range to 1000 ng/mL, meeting FDA and EMA bioanalytical method validation guidance requirements.
The typical MRM transition monitored for tirzepatide is m/z 1204.4 (precursor, [M+5H]5+) to m/z 1473.6 (product), with semaglutide often used as an internal standard (m/z 1029.4 to m/z 1238.4). Sample preparation typically uses protein precipitation with methanol; chromatographic separation uses a peptide C18 column (300 angstrom pore) with gradient elution of water and acetonitrile containing 0.1% formic acid. Intra- and inter-day accuracy and precision must meet regulatory criteria: accuracy within +/-15% of nominal concentration (within +/-20% at LLOQ) and CV <15% (CV <20% at LLOQ) across all quality control levels.
These bioanalytical methods support: pharmacokinetic studies in drug development (characterizing tirzepatide’s ~5-day half-life and subcutaneous bioavailability of ~62%); therapeutic drug monitoring in clinical settings; and comparative pharmacokinetic assessment in biosimilar/follow-on development.
Aggregation and Higher-Order Structure: SEC and Biophysical Methods
Size Exclusion Chromatography (SEC) separates peptide and protein species by hydrodynamic radius, enabling detection and quantification of aggregated species (dimers, trimers, higher-order oligomers, and particulates) that may compromise both safety (immunogenic potential) and efficacy (reduced receptor binding). Since tirzepatide exists as a trimer in solution with MW ~13,000 Da, SEC method development must account for this physiologically relevant oligomeric state and distinguish it from pathological aggregates formed under stress conditions or from manufacturing impurities.
Forced degradation studies expose tirzepatide to thermal stress (40-60°C), oxidative stress (H2O2), photolytic stress (ICH Q1B), and freeze-thaw cycling to characterize the drug’s degradation pathways and identify potential degradation products for stability-indicating method development. The oxidized mono-tirzepatide species (tryptophan oxidation, +16 Da, m/z 1208.1 at 5+) is a known potential degradation product under oxidative conditions.
Injectable Product Safety Testing: Endotoxins and Sterility
Tirzepatide is administered by subcutaneous injection — meaning endotoxin testing and sterility testing are mandatory safety tests for every batch of finished drug product (DP).
The Bacterial Endotoxins Test (BET) — performed by the Limulus Amebocyte Lysate (LAL) method per USP <85> — must confirm endotoxin below 1.0 EU/mL for parenteral products. Elevated endotoxins cause fever, septic shock, and death; this is the primary safety test distinguishing a sterile injectable from a potentially lethal product. For compounded tirzepatide, the absence of validated BET testing in many compounding operations was a significant quality gap.
Sterility testing per USP <71> — using both Soybean Casein Digest Medium (SCDM, incubated at 20-25°C) and Fluid Thioglycollate Medium (FTM, 30-35°C) for 14 days — confirms the absence of viable aerobic, anaerobic, and fungal microorganisms. For lyophilized products (common format for tirzepatide in research and compounding contexts), reconstitution procedure and container closure integrity also require validation.
Immunogenicity Testing
Because tirzepatide is an acylated synthetic peptide with non-natural amino acid substitutions and a fatty acid modification, there is inherent potential for the immune system to recognize it as foreign and generate anti-drug antibodies (ADAs). Immunogenicity testing per ICH S6(R1) guidance involves a tiered approach:
- Screening assay: Electrochemiluminescence (ECL) or enzyme-linked immunosorbent assay (ELISA) to detect the presence/absence of ADAs in patient plasma samples.
- Confirmatory assay: Competitive inhibition to confirm the specificity of detected ADAs to tirzepatide.
- Titration and characterization: Determination of ADA titer; classification as neutralizing or non-neutralizing antibodies (NAbs detected by receptor binding inhibition or cell-based assays).
ADA data from tirzepatide clinical trials (SURPASS and SURMOUNT programs) showed low overall immunogenicity rates consistent with other approved GLP-1 receptor agonists. Monitoring for immunogenicity in post-marketing pharmacovigilance supports the drug’s ongoing safety profile.
Stability Testing (ICH Q1A/Q5C)
Stability testing establishes that tirzepatide maintains its identity, purity, potency, and safety profile throughout its labeled shelf life under intended storage conditions. The FDA-approved Mounjaro and Zepbound products are labeled for storage at 2-8°C (refrigerated), with the option for room temperature storage (up to 30°C) for up to 21 days after first use.
ICH Q1A(R2) stability protocol for pharmaceutical products and ICH Q5C for biological products govern stability study design. For tirzepatide, stability-indicating methods must detect and separate the main drug substance peak from degradation products, including oxidized species, deamidated variants, clipped sequences (proteolytic fragments), and aggregate species. Forced degradation studies under all four ICH-specified stress conditions (heat, light, acid/base hydrolysis, oxidation) define the degradation pathways and confirm method specificity.
Analytical Method Validation (ICH Q2(R1))
All quantitative analytical methods used for tirzepatide release, stability, and impurity testing must be validated per ICH Q2(R1) (Method Validation) to demonstrate: specificity (absence of interference from related substances and matrix components); linearity (concentration-response across the working range); range; accuracy (trueness of recovery, typically demonstrated by spiked samples at 80%, 100%, 120% of specification); precision (repeatability and intermediate precision); detection limit (LOD) and quantitation limit (LOQ); and robustness (resistance to small deliberate variations in method parameters). For bioanalytical methods, validation follows the FDA Bioanalytical Method Validation Guidance (2018) or EMA equivalent.
Finding Accredited Tirzepatide Testing Laboratories
Tirzepatide testing spans multiple specialized capabilities: peptide HPLC purity analysis with wide-pore columns; LC-MS/MS bioanalysis at ng/mL concentrations in biological matrices; SEC aggregation profiling; immunogenicity assay development; endotoxin testing; sterility testing; and stability studies under ICH-compliant conditions. Few single laboratories offer all of these capabilities — most pharmaceutical tirzepatide testing programs use a combination of specialized CROs for different assay categories.
ContractLaboratory.com connects pharmaceutical companies, CROs, compounding pharmacies, and research organizations with accredited testing laboratories experienced in therapeutic peptide analysis, including pharmacology and drug development testing, biopharmaceutical potency testing, and related bioanalytical services. Submit a testing request specifying your test type, applicable ICH guidelines, sample matrix, and required turnaround. Qualified laboratories will respond with proposals. For guidance, contact our team.
Frequently Asked Questions About Tirzepatide Testing
Tirzepatide (brand names Mounjaro for type 2 diabetes, Zepbound for obesity and sleep apnea) is a dual agonist that activates both the GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors simultaneously. Semaglutide (Ozempic, Wegovy) is a selective GLP-1 receptor agonist only. The dual mechanism of tirzepatide produces greater weight loss and glycemic control in head-to-head comparisons. Structurally, tirzepatide is a 39-amino acid acylated peptide (MW ~4,813 Da) with a C20 fatty diacid moiety at Lys26, giving it specific analytical challenges, including the need for wide-pore HPLC columns. Semaglutide is a 31-amino acid GLP-1 analogue with a C18 fatty diacid at Lys34.
As of April 2026, routine compounding of tirzepatide, which is essentially a copy of Mounjaro or Zepbound is not legally permitted. FDA removed tirzepatide from its drug shortage list on December 19, 2024. Enforcement discretion periods for compounders ended February 18, 2025 (503A pharmacies) and March 19, 2025 (503B outsourcing facilities). A US District Court upheld the FDA’s decision in May 2025. Limited, patient-specific compounding may still occur under Section 503A when a prescriber documents a clinical need that cannot be met by the commercially available approved product — but mass compounding for general distribution is prohibited. Litigation regarding these determinations continues at the appellate level.
Standard small-molecule HPLC columns (100-130 angstrom pore) are not suitable for tirzepatide because the C20 fatty acyl modification significantly increases the peptide’s hydrophobicity and size, leading to poor peak shape and inadequate resolution of related substance impurities. Wide-pore reversed-phase columns — typically 300 angstrom pore C18 or C4 stationary phases (2.1 mm or 4.6 mm ID, 50-150 mm length) — provide appropriate retention and resolution. A shallow acetonitrile gradient with 0.1% TFA or 0.1% formic acid as ion-pairing modifier at low pH is standard. UHPLC systems offer improved resolution and throughput compared to standard HPLC and are preferred for regulatory submissions.
Tirzepatide bioanalysis by LC-MS/MS in positive electrospray ionization mode uses multiple charge states. The dominant and preferred MRM transition for tirzepatide is the [M+5H]5+ precursor ion at m/z 1204.4, monitoring the product ion at m/z 1473.6. The [M+4H]4+ at approximately m/z 1205 and [M+3H]3+ are also observed but less commonly used as primary transitions. For the mono-oxidized degradation product (e.g., tryptophan oxidation), the [M+5H]5+ shifts to m/z 1208.1 (+3.7 m/z units for a +16 Da mass increase). Semaglutide ([M+4H]4+ at m/z 1029.4 to m/z 1238.4) is commonly used as the internal standard due to its structural similarity to tirzepatide.
Bacterial Endotoxins Testing (BET) per USP <85> using the Limulus Amebocyte Lysate (LAL) method is mandatory for all injectable tirzepatide products, including compounded formulations. For parenteral products, the endotoxin limit is typically <1.0 EU/mL. The test must be performed on each batch before release. Methods include the gel-clot assay, turbidimetric assay, and chromogenic assay, with the kinetic chromogenic or turbidimetric methods preferred for their quantitative accuracy and reduced variability. For compounded tirzepatide, endotoxin testing was a significant quality gap during the shortage period, with the FDA expressing specific concern about compounders operating without validated BET procedures.
During the compounding period, many compounders combined tirzepatide with vitamin B12 (hydroxocobalamin or methylcobalamin) in the same vial for injection. Research published in 2025-2026 identified a novel impurity — a tirzepatide-B12 adduct — in these combination products, characterizing it by mass spectrometry and NMR spectroscopy. This adduct forms through covalent or strong non-covalent interaction between tirzepatide and B12. The adduct is absent from Eli Lilly’s approved Mounjaro and Zepbound formulations. Its functional impact on GIP and GLP-1 receptor binding, pharmacokinetics, and long-term safety is unknown. This finding illustrates why validated analytical testing — including peptide mapping by LC-MS/MS and adduct screening — is essential for compounded combination drug products.
ICH Q6B (Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products) applies to therapeutic peptides, including tirzepatide, and specifies the characterization and testing program expected for biologics and synthetic therapeutic peptides. Required characterization includes: physico-chemical characterization (molecular weight, amino acid sequence, post-synthetic modifications including acylation); biological activity (receptor binding or cell-based potency assay); immunochemical properties; purity and impurity analysis (process-related and product-related impurities by orthogonal analytical methods); quantity (content/concentration per dose); and safety-related tests (endotoxins, sterility, particulates). Release specifications and stability program requirements are also covered. ICH Q2(R1) governs validation of all quantitative analytical methods.
As of April 2026, tirzepatide has three FDA-approved indications under two brand names: (1) Mounjaro: approved May 2022 for glycemic control in adults with type 2 diabetes mellitus, as an adjunct to diet and exercise. (2) Zepbound: approved November 2023 for chronic weight management in adults with obesity (BMI >/=30) or overweight (BMI >/=27) with at least one weight-related comorbidity. (3) Zepbound: approved December 2024 for moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity — making tirzepatide the first medication approved specifically for OSA. Both Mounjaro and Zepbound contain the same active ingredient (tirzepatide) at the same doses, delivered via the same injection mechanism, differing primarily in labeling and indication.
Conclusion
Tirzepatide’s journey from breakthrough clinical compound to the center of a national compounding controversy to its current status as a commercially normalized, broadly available prescription drug represents one of the most rapid and complex pharmaceutical quality evolutions in recent memory. The compounding period — though now closed — generated an enormous body of independent quality testing data, identified real safety signals (adverse events, impurities, potency discrepancies), and demonstrated precisely why rigorous laboratory testing protocols matter for peptide drugs.
Whether testing for pharmaceutical manufacturing quality control under ICH Q6B and Q2(R1), for bioanalytical support of clinical pharmacokinetics, or for research-grade potency and purity verification, tirzepatide requires testing laboratories with specific expertise in acylated therapeutic peptides: wide-pore chromatography, high-resolution LC-MS/MS, SEC aggregation analysis, validated endotoxin and sterility testing, and immunogenicity assay capability.
ContractLaboratory.com connects organizations requiring tirzepatide testing with accredited pharmaceutical testing laboratories and biopharmaceutical testing specialists experienced across the full testing spectrum. Submit a testing request or contact our team to find the right laboratory for your specific tirzepatide testing needs.